US FDA accepts Biocon's cancer drug application for review

Biocon and Mylan’s proposed biosimilar bevacizumab, a cancer drug, is expected to be the third biosimilar from the partnered portfolio for patients in the US.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2wBiv7X
via IFTTT

0 comments:

Post a Comment